FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
Executive Summary
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly
You may also be interested in...
MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients
MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients
Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic